C Cadrenal Therapeutics, Inc.: management transactions · United States · SEC (Form 4) Browse the full insider trade history of Cadrenal Therapeutics, Inc., a publicly traded company based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Market capitalisation: €12.2m. The latest transaction was disclosed on 2 June 2026 (Cession). Among the most active insiders: Pham Quang X. The full history is free.
€141,595
11 ops.
Sell Volume
Buys €81,631 €141,595 Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Last declaration on 2 June 2026
All Executives22 Thresholds0 Prospectus0 Other0
Declarations 22 total
▼ CEO and Chairman · Executives · 29 May 2026
303 shares @ US$5.01 0.8% of flow Common Stock SEC:0001213900-26-064357:0
▼ CEO and Chairman · Executives · 2 Jun 2026
349 shares @ US$4.46 0.8% of flow Common Stock SEC:0001213900-26-064357:1
▼ CEO and Chairman · Executives · 11 May 2026
6,476 shares @ US$5.76 18.9% of flow Common Stock SEC:0001213900-26-062862:0
▼ CEO and Chairman · Executives · 12 May 2026
3,298 shares @ US$5.28 8.8% of flow Common Stock SEC:0001213900-26-062862:1
▼ CEO and Chairman · Executives · 28 May 2026
2,989 shares @ US$4.93 7.6% of flow Common Stock SEC:0001213900-26-062862:2
▼ CEO and Chairman · Executives · 22 May 2026
1,165 shares @ US$5.69 3.4% of flow Common Stock SEC:0001213900-26-061167:0
▼ CEO and Chairman · Executives · 24 Oct 2025
1,129 shares @ US$14.03 8.1% of flow Common Stock SEC:0001213900-25-103146:0
▼ CEO and Chairman · Executives · 27 Oct 2025
1,315 shares @ US$13.99 9.4% of flow Common Stock SEC:0001213900-25-103146:1
▼ Chief Financial Officer · Executives · 24 Oct 2025
1,800 shares @ US$13.99 48.6% of flow Common Stock SEC:0001213900-25-103147:0
▼ Chief Financial Officer · Executives · 27 Oct 2025
1,800 shares @ US$13.99 48.5% of flow Common Stock SEC:0001213900-25-103147:1
▼ Chief Financial Officer · Executives · 6 Oct 2025
107 shares @ US$13.99 2.9% of flow Common Stock SEC:0001213900-25-097178:0
● CEO and Chairman · Executives · 10 Apr 2024
50,000 shares 0Common Stock SEC:0001213900-24-031923:0
● CEO and Chairman · Executives · 23 Oct 2023
85,000 shares 0Common Stock SEC:0001213900-24-012837:0
▲ Director · Executives · 4 Oct 2023
17,331 shares @ US$0.70 20.6% of flow Common Stock SEC:0001213900-23-081216:0
Ideal exit: 30 Jun 2024 (T+270) ▲ CEO and Chairman · Executives · 5 Sept 2023
20,000 shares @ US$0.91 10.1% of flow Common Stock SEC:0001213900-23-074336:0
Ideal exit: 1 Jun 2024 (T+270) ▲ CEO and Chairman · Executives · 1 Sept 2023
10,000 shares @ US$0.9318 5.1% of flow Common Stock SEC:0001213900-23-073551:0
Ideal exit: 28 May 2024 (T+270) ▲ Director · Executives · 21 Mar 2023
10,000 shares @ US$1.39 23.1% of flow Common Stock SEC:0001213900-23-022065:0
Ideal exit: 16 Dec 2023 (T+270) ▲ Director · Executives · 16 Mar 2023
20,000 shares @ US$1.6699 56.3% of flow Common Stock SEC:0001213900-23-020675:0
Ideal exit: 11 Dec 2023 (T+270) ◆ CEO and Chairman · Executives · 10 Feb 2023
25,000 shares @ US$1.94 26.9% of flow Common Stock SEC:0001213900-23-010504:0
● Director · Executives · 24 Jan 2023
514,792 shares Common Stock SEC:0001213900-23-004882:0
◆ Chief Financial Officer · Executives · 24 Jan 2023
50,000 shares 0Common Stock SEC:0001213900-23-004883:0
● Director · Executives · 24 Jan 2023
50,000 shares Common Stock SEC:0001213900-23-004886:0